Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 3/20 | 0.38 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.38 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.33 |
| ▸ | CYP2B6 | P20813 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.33 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.32 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.32 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL38660384 | 0.77 | CHRNB2 (0.37) | CHRNB2CHRNA4 | |
| SCHEMBL2891613 | 0.77 | CHRNB2 (0.37) | CHRNB2CHRNA4 | |
| SCHEMBL5424020 | 0.75 | KMT2A (0.42) | CHRNB2CHRNA4 | |
| SCHEMBL27657607 | 0.75 | CHRNA3 (0.41) | CHRNB2CHRNA4 | |
| SCHEMBL30726705 | 0.75 | MPO (0.43) | — | |
| SCHEMBL29241951 | 0.75 | MPO (0.43) | — | |
| SCHEMBL15750456 | 0.75 | TRPV4 (0.47) | CHRNB2CHRNA4 | |
| SCHEMBL29630954 | 0.75 | TRPV4 (0.47) | CHRNB2CHRNA4 | |
| SCHEMBL27941820 | 0.72 | SLC7A5 (0.42) | CHRNB2CHRNA4 | |
| SCHEMBL31026422 | 0.72 | NNMT (0.44) | CHRNB2CHRNA4CYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118307565-A | FHND507 and 507 synthesis method | 南京师范大学 | 2024-07-09 | — | — | CN | claimed |
| EP-4722211-A1 | FGFR2/3 SELECTIVE INHIBITOR, PHARMACEUTICAL COMPOSITION AND USE THEREOF | Changchun Genescience Pharmaceutical Co., Ltd. (CN) | 2026-04-08 | — | — | EP | disclosed |
| CN-119264042-A | Cyclopentane derivative-containing inhibitor, preparation method and application thereof | 上海翰森生物医药科技有限公司 | 2025-01-07 | — | — | CN | disclosed |
| US-20240343691-A1 | COMPOSITIONS FOR MODULATING A KINASE CASCADE AND METHODS OF USE THEREOF | ATNX SPV LLC (US) | 2024-10-17 | — | — | US | disclosed |
| CN-114071999-B | 1-Phenyl-5-azinylpyrazolyl-3-oxyalkyl acids and their use for controlling unwanted plant growth | 拜耳公司 | 2024-08-27 | — | — | CN | disclosed |
| CN-118307565-A | FHND507 and 507 synthesis method | 南京师范大学 | 2024-07-09 | — | — | CN | disclosed |
| CN-118307565-A | FHND507 and 507 synthesis method | 南京师范大学 | 2024-07-09 | — | — | CN | disclosed |
| CN-116535389-B | 6-Pyridine-3-quinoxaline urea derivative and application thereof | 四川大学 | 2024-05-03 | — | — | CN | disclosed |
| CN-116535389-A | 6-pyridine-3-quinoxaline urea derivative and application thereof | 四川大学 | 2023-08-04 | — | — | CN | disclosed |
| CN-116490186-A | Compounds for targeted degradation of RET | C4医药公司 | 2023-07-25 | — | — | CN | disclosed |
| EP-2217229-A1 | PHARMACEUTICAL COMPOSITIONS FOR MODULATING A KINASE CASCADE AND METHODS OF USE THEREOF | Kinex Pharmaceuticals, LLC (US) | 2010-08-18 | — | — | EP | disclosed |
| EP-2155681-A1 | PROCESS FOR THE PREPARATION OF COMPOSITIONS FOR MODULATING A KINASE CASCADE AND METHODS OF USE THEREOF | Kinex Pharmaceuticals, LLC (US) | 2010-02-24 | — | — | EP | disclosed |
| US-20090318450-A1 | COMPOSITIONS FOR MODULATING A KINASE CASCADE AND METHODS OF USE THEREOF | KINEX PHARMACEUTICALS, LLC (US) | 2009-12-24 | — | — | US | disclosed |
| EP-2114934-A1 | COMPOSITION AND METHODS FOR MODULATING A KINASE CASCADE | Kinex Pharmaceuticals, LLC (US) | 2009-11-11 | — | — | EP | disclosed |
| WO-2009051848-A1 | PHARMACEUTICAL COMPOSITIONS FOR MODULATING A KINASE CASCADE AND METHODS OF USE THEREOF | KINEX PHARMACEUTICALS, LLC (US) | 2009-04-23 | — | — | WO | disclosed |
| WO-2008144045-A1 | PROCESS FOR THE PREPARATION OF COMPOSITIONS FOR MODULATING A KINASE CASCADE AND METHODS OF USE THEREOF | KINEX PHARMACEUTICALS, LLC (US) | 2008-11-27 | — | — | WO | disclosed |
| US-20080287436-A1 | Process for the preparation of compositions for modulating a kinase cascade and methods of use thereof | SAGARD HEALTHCARE ROYALTY PARTNERS, LP, AS ADMINISTRATIVE AGENT (CA) | 2008-11-20 | — | — | US | disclosed |
| WO-2008082637-A9 | COMPOSITION AND METHODS FOR MODULATING A KINASE CASCADE | KINEX PHARMACEUTICALS LLC (US) | 2008-09-18 | — | — | WO | disclosed |
| US-20080221102-A1 | Composition and methods for modulating a kinase cascade | SAGARD HEALTHCARE ROYALTY PARTNERS, LP, AS ADMINISTRATIVE AGENT (CA) | 2008-09-11 | — | — | US | disclosed |
| WO-2008082637-A1 | COMPOSITION AND METHODS FOR MODULATING A KINASE CASCADE | KINEX PHARMACEUTICALS, LLC (US) | 2008-07-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221102-A1 | Composition and methods for modulating a kinase cascade | MAP3K4, MAP3K6, MAP3K3 | CHRNB2 2343/4885CHRNA4 3685/4885CYP2A6 4733/4885 |
| US-20080287436-A1 | Process for the preparation of compositions for modulating a kinase cascade and methods of use thereof | MAP3K2, MAP3K6, MAP3K4 | CHRNB2 2093/4885CHRNA4 2936/4885CYP2A6 4128/4885 |
| US-20090318450-A1 | COMPOSITIONS FOR MODULATING A KINASE CASCADE AND METHODS OF USE THEREOF | MAP3K2, MAP3K4, MAP3K5 | CHRNB2 1981/4885CHRNA4 2349/4885CYP2A6 4466/4885 |
| US-20240343691-A1 | COMPOSITIONS FOR MODULATING A KINASE CASCADE AND METHODS OF USE THEREOF | MAP3K2, MAP3K4, MAP3K5 | CHRNB2 1981/4885CHRNA4 2349/4885CYP2A6 4466/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.